

JOURNAL OF  
**Pharmaceutical  
Sciences**

September 1963

volume 52      number 9

EDWARD G. FELDMANN,  
*editor*

SAMUEL W. GOLDSTEIN,  
*associate editor*

ROBERT F. STEEVES,  
*assistant editor*

SANDRA SUE SMITH,  
*editorial assistant*

*Editorial Advisory Board*

J. H. BURCKHALTER

TROY C. DANIELS

GEORGE P. HAGER

W. W. HILTY

THOMAS J. MACEK

VARRO E. TYLER, JR.

*Committee on Publications*

LINWOOD F. TICE, *chairman*

WILLIAM S. APPLE

GROVER C. BOWLES

HENRY M. BURLAGE

HUGO H. SCHAEFER

The *Journal of Pharmaceutical Sciences* is published monthly by the American Pharmaceutical Association, at 20th & Northampton Sts., Easton, Pa. Second-class postage paid at Easton, Pa., and at additional mailing office.

All expressions of opinion and statements of supposed fact appearing in articles or editorials carried in THIS JOURNAL are published on the authority of the writer over whose name they appear, and are not to be regarded as necessarily expressing the policies or views of the American Pharmaceutical Association.

Offices—Editorial, Advertising, and Subscription Offices: 2215 Constitution Ave., N. W., Washington, D. C. 20037. Publication Offices: 20th & Northampton Streets, Easton, Pa.

Annual Subscription—United States and foreign, \$15.00; single copies, \$1.50; combined rate with the *Journal of the American Pharmaceutical Association*, \$20.00. Subscription rates are subject to change without notice. Members of the American Pharmaceutical Association may elect to receive the *Journal of Pharmaceutical Sciences* as a part of their annual \$27.00 A.P.A. membership dues.

Claims—Missing numbers will not be supplied if claims are received more than 60 days after the date of the issue, or if loss was due to failure to give notice of change of address. The Association cannot accept responsibility for foreign delivery when its records indicate shipment has been made.

Change of Address—Members and subscribers should notify at once both the Post Office and the American Pharmaceutical Association, 2215 Constitution Ave., N. W., Washington, D. C. 20037, of any change of address.

© Copyright 1963, American Pharmaceutical Association, 2215 Constitution Ave., N. W., Washington, D. C. 20037.

— *The Editor comments* —

SELECTION OF ADVISORS FOR FDA

Considerable support has come from various quarters to the recommendation embodied in the 1962 Citizens Advisory Committee report on the federal Food and Drug Administration which suggested that the agency should have the benefit of outside advisory committees. Such panels of experts would provide counsel to FDA on the highly complex scientific questions which arise from time to time in the course of administering its responsibilities as defined under pertinent sections of the Federal Food, Drug, and Cosmetic Act, its amendments and regulations.

We endorse and support this view and urge its early and wide implementation. However, we have noted with some concern that most, if not all, discussion and consideration of this recommendation have been solely in terms of completely medically-oriented advisory bodies which would consider medical questions and problems. Our concern is that—as in the case of the *Commission on Drug Safety* about which we commented in the August issue of THIS JOURNAL—the FDA may overlook the fact that many of the problems which it now faces and will be facing in the immediate future, have pharmaceutical ramifications of major significance.

Consequently, we feel that adequate recognition of this situation is also necessary on the part of FDA officials in order that knowledgeable pharmaceutical scientists might be appointed to the committees considering medical questions. Furthermore, it is our opinion that separate committees, composed *primarily* of scientists from various appropriate disciplines, should be established to study and advise specifically on those medically-related problems about which such panels would most properly be concerned. *The fact must be recognized that many of the present complex questions concerning the safety, efficacy, and quality of drugs are basically concerned with the pharmaceutical sciences, and are only indirectly or incidentally of a medical nature.*

*Edward G. Feldmann*